Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: temozolomide

« Back to Dashboard

Summary for Generic Name: temozolomide

Drug Master File Entries: see list15
Suppliers: see list3

Pharmacology for Ingredient: temozolomide

Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity

Clinical Trials for: temozolomide

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Status: Completed Condition: Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor

Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Status: Completed Condition: Recurrent Central Nervous System Neoplasm

Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Status: Completed Condition: Glioblastoma; Glioma; Astrocytoma

Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Status: Active, not recruiting Condition: Neuroblastoma

Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Status: Terminated Condition: Brain Cancer; Glioblastoma Multiforme

A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma
Status: Completed Condition: Melanoma

Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Status: Active, not recruiting Condition: Glioblastoma Multiforme; Gliosarcoma

ABT-888 and Temozolomide for Liver Cancer
Status: Active, not recruiting Condition: Hepatocellular Carcinoma

Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients
Status: Recruiting Condition: Glioblastoma

Sarasar and Temodar for Glioblastoma Multiforme Patients
Status: Active, not recruiting Condition: Glioblastoma Multiforme; Gliosarcoma; Brain Tumors

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
POWDER;INTRAVENOUS022277Feb 27, 2009RXYes7,786,118<disabled>Y<disabled>
Merck Sharp Dohme
POWDER;INTRAVENOUS022277Feb 27, 2009RXYes6,987,108<disabled>Y<disabled>
Merck Sharp Dohme
POWDER;INTRAVENOUS022277Feb 27, 2009RXYes8,623,868<disabled>Y<disabled>
Sun Pharma Global
CAPSULE;ORAL201742Feb 12, 2014RXNo<disabled><disabled>
Merck Sharp Dohme
CAPSULE;ORAL021029Aug 11, 1999RXNo5,260,291*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn